Mycophenolsäure Accord (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mycophenolsäure Accord, is an immunosuppressant presented as an oral formulation for oral use. It is used to prevent organ transplant rejection and to treat selected autoimmune diseases by inhibiting lymphocyte proliferation in adult patients.

GNH USA supplies Mycophenolsäure Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the supply chain.

Mycophenolic Acid is an immunosuppressive agent used in transplantation and autoimmune disease pathways.

Organ transplant rejection: reduces the risk of acute rejection by suppressing T‑cell activity. Kidney transplant: helps maintain graft function and prolong survival of the transplanted kidney. Autoimmune diseases: controls disease activity in conditions such as lupus nephritis by limiting lymphocyte proliferation.

Mycophenolic Acid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Diarrhea - Abdominal pain - Headache

Serious or Rare Side Effects: - Leukopenia or other bone‑marrow suppression - Severe or opportunistic infections - Elevated liver enzymes or hepatitis

Use of Mycophenolic Acid requires careful monitoring and patient education. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: check serum creatinine and eGFR periodically. - Evaluate liver enzymes: conduct periodic LFTs for hepatotoxicity. - Avoid live vaccines: immunosuppression increases risk of vaccine‑derived infection. - Pregnancy risk: use only if clearly needed; safety category unknown. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mycophenolic Acid can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: combined use markedly increases myelosuppression. - Cyclosporine: may raise mycophenolic acid plasma concentrations. - Tacrolimus: can lead to elevated exposure and toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may impair renal function when combined. - Rifampin: induces metabolism, reducing mycophenolic acid levels. - Cholestyramine: binds drug in gut, decreasing absorption. - ACE inhibitors or ARBs: monitor renal parameters due to additive nephrotoxic potential.